Skip to main content
SpringerLink
Log in

Forensic Toxicology of Stimulants and Psychotropic Drugs

  • Chapter
  • First Online:
Book cover Forensic Medicine and Human Cell Research

Part of the book series: Current Human Cell Research and Applications ((CHCRA))

  • 545 Accesses

Abstract

Methamphetamine, a representative stimulant, is one of the most commonly abused drugs globally. Although originally used in healthcare settings as a psychostimulant among the psychotropic drugs, it has been illegally bootlegged and abused because of its strong pharmacological action. Methamphetamine is a central nervous system stimulant that induces hypernoia and reduces fatigue and drowsiness. However, its abuse can lead to dependence and the development of psychosis, with the chief complaints of hallucinations and delusions. Its use is therefore restricted by law. In terms of psychotropic drugs, whether old or new type of drugs are prescribed depends on symptoms even now. Psychotropic drugs that have high lethality associated with overdose include typical antipsychotics, tricyclic antidepressants, and barbiturates. Even drugs that have few side effects and are considered safe, such as atypical antipsychotics, selective serotonin reuptake inhibitors, benzodiazepines, and non-benzodiazepines, are associated with a risk for overdose, increased suicide rates, and onset of discontinuation syndrome where they are prescribed more than necessary. Individuals can form physical and psychological dependence to benzodiazepines and barbiturates, and therefore attention must be paid to their long-term use.

In this chapter, we provide an evidence-based review of the social problems caused by stimulants (abused drugs) and psychotropic drugs (medicinal drugs), as well as their pharmacological actions and symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Suwaki H, Fukui S, Konuma K. Methamphetamine abuse in Japan: its 45 year history and the current situation. In: Klee H, editor. Amphetamine misuse: international perspective on current trends. Amsterdam: CRC; 1997. p. 199–214.

    Google Scholar 

  2. United Nations Office on Drugs and Crime. World Drug Report 2017. https://www.unodc.org/wdr2017/. Accessed 24 Jan 2018.

  3. Ashok AH, Mizuno Y, Volkow ND, Howes OD. Association of stimulant use with dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: a systematic review and meta-analysis. JAMA Psychiat. 2017;74(5):511–9.

    Article  Google Scholar 

  4. Aikawa Y, Ogai Y, Morita N, Umeno M, Okada N, Ikeda T, et al. A change of patients with methamphetamine-related disorders admitted to Tokyo metropolitan Matsuzawa hospital—the comparison between the second and third epidemics of methamphetamine abuse in Japan. Nihon Arukoru Yakubutsu Igakkai Zassi. 2012;47(2):57–67.

    Google Scholar 

  5. Thomas AB. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007;3(4):495–500.

    Google Scholar 

  6. Bechtel LK, Holstege CP. Criminal poisoning: drug-facilitated sexual assault. Emerg Med Clin North Am. 2007;25(2):499–525.

    Article  Google Scholar 

  7. Farrugia LA, Rhyee SH, Campleman SL, Ruha AM, Weigand T, Wax PM, et al. The toxicology investigators consortium case registry-the 2015 experience. J Med Toxicol. 2016;12(3):224–47.

    Article  CAS  Google Scholar 

  8. Shimane T, Matsumoto T, Wada K. Clinical behavior of Japanese community pharmacists for preventing prescription drug overdose. Psychiatry Clin Neurosci. 2015;69(4):220–7.

    Article  Google Scholar 

  9. Nakagawa T, Kaneko S. Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3,4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N,N-diisopropyltryptamine (foxy). J Pharmacol Sci. 2008;106(1):2–8.

    Article  CAS  Google Scholar 

  10. Nishiguchi M, Kinoshita H, Kasuda S, Takahashi M, Yamamura T, Matsui K, et al. Effects of dopamine antagonists on methamphetamine-induced dopamine release in high and low alcohol preference rats. Toxicol Mech Methods. 2010;20(3):127–32.

    Article  CAS  Google Scholar 

  11. Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res. 2008;14(2–3):169–83.

    Article  Google Scholar 

  12. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75(6):406–33.

    Article  CAS  Google Scholar 

  13. Cho AK, Melega WP. Patterns of methamphetamine abuse and their consequences. J Addict Dis. 2002;21(1):21–34.

    Article  Google Scholar 

  14. Nickell JR, Siripurapu KB, Vartak A, Crooks PA, Dwoskin LP. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol. 2014;69:71–106.

    Article  CAS  Google Scholar 

  15. Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell. 2015;162(4):712–25.

    Article  CAS  Google Scholar 

  16. Wise RA, Rompre PP. Brain dopamine and reward. Annu Rev Psychol. 1989;40:191–225.

    Article  CAS  Google Scholar 

  17. Zalis EG, Lundberg GD, Knutson RA. The pathophysiology of acute amphetamine poisoning with pathologic correlation. J Pharmacol Exp Ther. 1967;158(1):115–27.

    CAS  PubMed  Google Scholar 

  18. Zhu BL, Oritani S, Shimotouge K, Ishida K, Quan L, Fujita MQ, et al. Methamphetamine-related fatalities in forensic autopsy during 5 years in the southern half of Osaka city and surrounding areas. Forensic Sci Int. 2000;113(1–3):443–7.

    Article  CAS  Google Scholar 

  19. Kaya S, McKetin R. Cardiotoxicity associated with methamphetamine use and signs of cardiovascular pathology among methamphetamine users. National Drug and Alcohol Research Center Technical Report No. 238. National Drug and Alcohol Research Center. Australia. 2005.

    Google Scholar 

  20. Kaya S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007;102(8):1204–11.

    Article  Google Scholar 

  21. Cloutier RL, Hendrickson RG, Fu RR, Blake B. Methamphetamine-related psychiatric visits to an urban academic emergency department: an observational study. J Emerg Med. 2013;45(1):136–42.

    Article  Google Scholar 

  22. Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care. 2011;38(1):41–58.

    Article  Google Scholar 

  23. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009;104(7):1085–99.

    Article  Google Scholar 

  24. Schep LJ, Slaughter RJ, Beasley DM. The clinical toxicology of metamfetamine. Clin Toxicol. 2010;48(7):675–94.

    Article  CAS  Google Scholar 

  25. Baselt RC. Disposition of toxic drugs and chemicals in man. 8th ed. Foster City: Biomedical Publications; 2008.

    Google Scholar 

  26. Kim I, Oyler JM, Moolchan ET, Cone EJ, Huestis MA. Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit. 2004;26(6):664–72.

    Article  CAS  Google Scholar 

  27. Nagata T. Toxicological examination from the medico-legal aspects. Nihon Hoigaku Zassi. 1986;40(5):455–64.

    CAS  Google Scholar 

  28. Nagata T. Signification of methamphetamine concentration in body fluids and tissues. Nihon Hoigaku Zassi. 1983;37(5):513–8.

    CAS  Google Scholar 

  29. Fukunaga T, Mizoi Y, Adachi J, Tatsuno Y, Fujiwara S, Ueno Y. Methamphetamine concentrations in blood, urine, and organs of fatal cases after abuse. Jpn J Leg Med. 1987;41(4):328–34.

    CAS  Google Scholar 

  30. Fukunaga T, Mizoi Y, Adachi J. Methamphetamine-induced changes peripheral catecholamines: an animal experiment to elucidate the cause of sudden death after methamphetamine abuse. Jpn J Leg Med. 1987;41(4):335–41.

    CAS  Google Scholar 

  31. Glasner-Edwards S, Mooney LJ. Methamphetamine psychosis: epidemiology and management. CNS Drugs. 2014;28(12):1115–26.

    Article  CAS  Google Scholar 

  32. Grant KM, LeVan TD, Wells SM, Li M, Stoltenberg SF, Gendelman HE, et al. Methamphetamine-associated psychosis. J Neuroimmune Pharmacol. 2012;7(1):113–39.

    Article  Google Scholar 

  33. Richards JR, Albertson TE, Derlet RW, Lange RA, Olson KR, Horowitz BZ. Treatment of toxicity from amphetamines, related derivatives, and analogues: a systematic clinical review. Drug Alcohol Depend. 2015;150:1–13.

    Article  CAS  Google Scholar 

  34. Shoptaw SJ, Kao U, Ling W. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2009;21(1):CD003026.

    Google Scholar 

  35. Ministry of Justice. Part 5, Repeat offense and repeat delinquency. Captor 2, Overview of repeat offense and repeat delinquency. Section 1. Arrest. In: Legal Research Institute, editor. White paper on crime: Tokyo, Showa Information Processing Corporation Press; 2017. p. 209.

    Google Scholar 

  36. Tani N, Chen JH, Michiue T, Oritani S, Ishikawa T. Retrospective investigation of psychostimulant-related fatalities in forensic autopsy during 10 years in the southern half of Osaka city and surrounding areas. Jpn J of Forensic Pathol. 2016;22(1):13–20.

    Google Scholar 

  37. Riley DE, Liu L, Cohen B, Robinson S, Groessl EJ, Ho SB. Characteristics and impact of methamphetamine use in patients with chronic hepatitis C. J Addict Med. 2014;8(1):25–32.

    Article  CAS  Google Scholar 

  38. Izumi K, Mine K, Inoue Y, Teshima M, Ogawa S, Kurafuji T, et al. Reduced Tyk2 gene expression in β-cells due to natural mutation determines susceptibility to virus-induced diabetes. Nat Commun. 2015;6:6748.

    Article  CAS  Google Scholar 

  39. Kashiwagi M, Hara K, Liu Z, Kageura M, Matsusue A, Sugimura T, et al. Diagnostic approach to drug-screening tests for fatal diabetic ketoacidosis: forensic autopsy of a methamphetamine abuser. Legal Med. 2010;12(4):192–4.

    Article  CAS  Google Scholar 

  40. Gilbert JD, Byard RW. Fatal diabetic ketoacidosis—a potential complication of MDMA (ecstasy) use. J Forensic Sci. 2018;63(3):939–41. https://doi.org/10.1111/1556-4029.13602.

    Article  PubMed  Google Scholar 

  41. Wong ML, Holt RI. The potential dangers of mephedrone in people with diabetes: a case report. Drug Test Anal. 2011;3(7–8):464–5.

    Article  CAS  Google Scholar 

  42. Hudepohl NS, Nasrallah HA. Antipsychotic drugs. Handbook Clin Neurol. 2012;106:657–67.

    Article  Google Scholar 

  43. Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs. 2012;26(7):601–11.

    Article  CAS  Google Scholar 

  44. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol. 1995;15(1 Suppl 1):4S–10S.

    Article  CAS  Google Scholar 

  45. Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2013;31(5):CD007815.

    Google Scholar 

  46. Khanna P, Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, El-Sayeh HG. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2014;2(1):CD006569.

    Google Scholar 

  47. Berman BD. Neuroleptic malignant syndrome: a review for neurohospitalists. Neurohospitalist. 2011;1(1):41–7.

    Article  Google Scholar 

  48. López-Muñoz F, Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr Pharm Des. 2009;15(14):1563–86.

    Article  Google Scholar 

  49. Shannon MW. Duration of QRS disturbances after severe tricyclicantidepressant intoxication. J Toxicol Clin Toxicol. 1992;30(3):377–86.

    Article  CAS  Google Scholar 

  50. Kerr G, McGuffie A, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J. 2001;18(4):236–41.

    Article  CAS  Google Scholar 

  51. Hosenbocus S, Chahal R. SSRIs and SNRIs: a review of the discontinuation syndrome in children and adolescents. J Can Acad Child Adolesc Psychiatry. 2011;20(1):60–7.

    PubMed  PubMed Central  Google Scholar 

  52. Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001;7(3):249–64.

    Article  CAS  Google Scholar 

  53. Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033–49.

    Article  CAS  Google Scholar 

  54. Craddock N, Sklar P. Genetics of bipolar disorder. Lancet. 2013;381(9878):165416–62.

    Article  Google Scholar 

  55. Ohnishi T, Murata T, Watanabe A, Hida A, Ohba H, Iwayama Y, et al. Defective craniofacial development and brain function in a mouse model for depletion of intracellular inositol synthesis. J Biol Chem. 2014;289(15):10785–96.

    Article  CAS  Google Scholar 

  56. Kuwabara H. Psychotropic drugs: anxiolytics and hypnotics. Chudoku Kenkyu. 2012;25(2):117–21.

    PubMed  Google Scholar 

  57. Olsen RW. Allosteric ligands and their binding sites define γ-aminobutyric acid (GABA) type a receptor subtypes. Adv Pharmacol. 2015;73:162–202.

    Google Scholar 

  58. Olsen RW. GABA-benzodiazepine-barbiturate receptor interactions. J Neurochem 1981;37(1):1–13, 1.

    Article  CAS  Google Scholar 

  59. Pétursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455–9.

    Article  Google Scholar 

  60. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev. 2000;4(6):551–81.

    Article  Google Scholar 

  61. López-Muñoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat. 2005;1(4):329–43.

    PubMed  PubMed Central  Google Scholar 

  62. Mactier R, Laliberté M, Mardini J, Ghannoum M, Lavergne V, Gosselin S, et al. Extracorporeal treatment for barbiturate poisoning: recommendations from the EXTRIP Workgroup. Am J Kidney Dis. 2014;64(3):347–58.

    Article  Google Scholar 

  63. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. J Am Med Assoc. 2013;309(7):657–9.

    Article  CAS  Google Scholar 

  64. Ministry of Health, Labor and Welfare Home Page. Overview of Suicide Death Statistics. Suicide seen by means. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/tokusyu/suicide04/10.html#2. Accessed 24 Jan 2018.

  65. Hikiji W, Okumura Y, Matsumoto T, Tanifuji T, Suzuki H, Takeshima T, et al. Identification of psychotropic drugs attributed to fatal overdose—a case-control study by data from the Tokyo Medical Examiner’s office and prescriptions. Seishin Shinkeigaku Zasshi. 2016;118(1):3–13.

    PubMed  Google Scholar 

  66. Japan Medical Association Mental Health Committee. Depression and suicide countermeasures in Japan. Jpn Med Assoc J. 2013;56(3):129–42.

    Google Scholar 

  67. World Health Organization. Substance abuse. http://www.who.int/topics/substance_abuse/en/. Accessed 24 Jan 2018.

  68. Alexander PD, Gicas KM, Willi TS, Kim CN, Boyeva V, Procyshyn RM, et al. A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. Psychopharmacology. 2017;234:1535–47.

    Article  CAS  Google Scholar 

  69. Sellers EM. Alcohol, barbiturate and benzodiazepine withdrawal syndromes: clinical management. Can Med Assoc J. 1988;139(2):113–20.

    CAS  Google Scholar 

  70. Namina M, Sugihara K, Watanabe Y, Sasa H, Umekage T, Okamoto K. Quantitative analysis of the effects of lithium on the reverse tolerance and the c-Fos expression induced by methamphetamine in mice. Brain Res Protocol. 1999;4(1):11–8.

    Article  Google Scholar 

  71. Yui K, Goto K, Ikemoto S, Ishiguro T. Monoamine neurotransmitter metabolites and spontaneous recurrence of methamphetamine psychosis. Brain Res Bull. 1997;43(1):25–33.

    Article  CAS  Google Scholar 

  72. Khanna JM, Kalant H, Chau A, Shah G. Rapid tolerance and crosstolerance to motor impairment effects of benzodiazepines, barbiturates, and ethanol. Pharmacol Biochem Behav. 1998;59(2):511–9.

    Article  CAS  Google Scholar 

  73. Voss J, Sanchez C, Michelsen S, Ebert B. Rotarod studies in the rat of the GABAA receptor agonist gaboxadol: lack of ethanol potentiation and benzodiazepine cross-tolerance. Eur J Pharmacol. 2003;482(1–3):215–22.

    Article  CAS  Google Scholar 

  74. McIntyre IM, Nelson CL, Schaber B, Hamm CE. Antemortem and postmortem methamphetamine blood concentrations: three case reports. J Anal Toxicol. 2013;37(6):386–9.

    Article  CAS  Google Scholar 

  75. Suzuki S, Inoue T, Hori H, Inayama S. Analysis of methamphetamine in hair, nail, sweat, and saliva by mass fragmentography. J Anal Toxicol. 1989;13(3):176–8.

    Article  CAS  Google Scholar 

  76. Brčić Karačonji I, Brajenović N. Evaluation of amphetamine-type stimulant abuse through hair analysis: results from 12 years of work. Arh Hig Rada Toksikol. 2014;65(2):225–30.

    Article  Google Scholar 

  77. Shu I, Jones J, Jones M, Lewis D, Negrusz A. Detection of drugs in nails: three year experience. J Anal Toxicol. 2015;39(8):624–8.

    Article  CAS  Google Scholar 

  78. Sugimura T, Hara K, Kubo S, Nishida T, Yuge R, Ishikura H. Comparative study of two urinary drug screening kits. Nihon Kyukyu Igakukai Zassi. 2012;23:842–50.

    Article  Google Scholar 

  79. Nishiguchi M, Kinoshita H, Higasa K, Taniguchi T, Ouchi H, Minami T, et al. The false positive reaction of the triage panel drug-of-abuse by herbal drugs ma-huang (Ephedra sinica (Ephedraceae)). Nihon Hoigaku Zassi. 2001;55(3):331–8.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Legal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, Japan

    Minori Nishiguchi & Hajime Nishio

Authors
  1. Minori Nishiguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hajime Nishio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minori Nishiguchi .

Editor information

Editors and Affiliations

  1. Department of Legal Medicine, Osaka City University Medical School, Osaka, Japan

    Takaki Ishikawa

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Nishiguchi, M., Nishio, H. (2019). Forensic Toxicology of Stimulants and Psychotropic Drugs. In: Ishikawa, T. (eds) Forensic Medicine and Human Cell Research. Current Human Cell Research and Applications. Springer, Singapore. https://doi.org/10.1007/978-981-13-2297-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-2297-6_5

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-2296-9

  • Online ISBN: 978-981-13-2297-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation